We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Read MoreHide Full Article
Penumbra (PEN - Free Report) is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are major dampeners for Penumbra. The stock carries a Zacks Rank #3 (Hold).
Factors Driving PEN Shares
Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In this region, the company is benefiting from sales of new products and further market penetration of existing products. In the fourth quarter of 2024, the company delivered 27.3% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0, and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 41% year over year.
Penumbra is still in the early stages of its journey to bring the company’s proprietary thrombectomy technologies to patients in the United States and around internationally. In terms of product launch, the Element Vascular Access System was launched in January 2025. This laser-cut hypotube sheath is designed for venous thromboembolism treatments and is compatible with the Lightning Flash 2.0 thrombectomy system.
Penumbra also launched its Lightning Bolt 12 and Lightning Bolt 6x with TraX in 2025. These additions to Penumbra's Computer-Assisted Vacuum Thrombectomy (CAVT) platform aim to enhance arterial and venous thrombus management. In terms of pipeline, the company plans to strongly focus on Flash and Bolt innovations.
Penumbra derives a significant portion of its revenue internationally (24.5% in 2025). The company expects to materially increase both revenues and profitability in the company’s international business in the next few years. During this period, it expects to bring its franchise products like RED catheters and CAT RX together with all its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams.
Over the past three months, shares of PEN have gained 16.7% against the industry’s 5.6% dip. The company’s consistent efforts to expand its high-growth thrombectomy business, as well as its array of new product launches, are expected to help the stock continue with its uptrend in the coming days.
Concerns Remain for Penumbra
A significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2024, approximately 29% of the company's consolidated revenues came from the non-U.S. markets. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses and consequently, net income.
Like other industry players, Penumbra’s business is currently impacted by worldwide geopolitical complications leading to widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra’s profitability. In the fourth quarter of 2024, the company incurred a 7.3% rise in the cost of revenues. Selling, general and administrative expenses rose 13.8% year over year.
Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 21.2% to 63 cents in the past 30 days. Shares of the company have surged 113% in the past year against the industry’s 10.8% fall. Its earnings yield of 1.8% also outpaces the industry’s -4.6% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Boston Scientific shares have rallied 49.6% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.
Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 1 cent to $7.94 in the past 30 days. Shares of the company have jumped 18.8% in the past year against the industry’s 3.5% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
Penumbra (PEN - Free Report) is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are major dampeners for Penumbra. The stock carries a Zacks Rank #3 (Hold).
Factors Driving PEN Shares
Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line of products. In this region, the company is benefiting from sales of new products and further market penetration of existing products. In the fourth quarter of 2024, the company delivered 27.3% year-over-year growth in thrombectomy in the United States, driven by continued adoption and further market penetration of the current CAVT Portfolio, Lightning Flash 2.0, and Lightning Bolt 7. The U.S. VTE franchise delivered revenue growth of 41% year over year.
Penumbra is still in the early stages of its journey to bring the company’s proprietary thrombectomy technologies to patients in the United States and around internationally. In terms of product launch, the Element Vascular Access System was launched in January 2025. This laser-cut hypotube sheath is designed for venous thromboembolism treatments and is compatible with the Lightning Flash 2.0 thrombectomy system.
Penumbra also launched its Lightning Bolt 12 and Lightning Bolt 6x with TraX in 2025. These additions to Penumbra's Computer-Assisted Vacuum Thrombectomy (CAVT) platform aim to enhance arterial and venous thrombus management. In terms of pipeline, the company plans to strongly focus on Flash and Bolt innovations.
Penumbra derives a significant portion of its revenue internationally (24.5% in 2025). The company expects to materially increase both revenues and profitability in the company’s international business in the next few years. During this period, it expects to bring its franchise products like RED catheters and CAT RX together with all its most advanced products, Lightning Flash, Lightning Bolt 7 and Thunderbolt, to Penumbra global teams.
Penumbra, Inc. Price
Penumbra, Inc. price | Penumbra, Inc. Quote
Over the past three months, shares of PEN have gained 16.7% against the industry’s 5.6% dip. The company’s consistent efforts to expand its high-growth thrombectomy business, as well as its array of new product launches, are expected to help the stock continue with its uptrend in the coming days.
Concerns Remain for Penumbra
A significant portion of Penumbra’s sales and costs are exposed to changes in foreign exchange rates. In 2024, approximately 29% of the company's consolidated revenues came from the non-U.S. markets. The company’s operations use multiple foreign currencies, including the euro and Japanese yen. Changes in those currencies relative to the U.S. dollar will impact its sales, cost of sales and expenses and consequently, net income.
Like other industry players, Penumbra’s business is currently impacted by worldwide geopolitical complications leading to widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. All these factors are putting significant pressure on Penumbra’s profitability. In the fourth quarter of 2024, the company incurred a 7.3% rise in the cost of revenues. Selling, general and administrative expenses rose 13.8% year over year.
Key Picks
Some better-ranked stocks in the broader medical space include Hims & Hers Health (HIMS - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 21.2% to 63 cents in the past 30 days. Shares of the company have surged 113% in the past year against the industry’s 10.8% fall. Its earnings yield of 1.8% also outpaces the industry’s -4.6% yield. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.
Boston Scientific shares have rallied 49.6% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $2.85 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.3%. In the last reported quarter, it posted an earnings surprise of 7.7%.
Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 1 cent to $7.94 in the past 30 days. Shares of the company have jumped 18.8% in the past year against the industry’s 3.5% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.